Blood glucose level monitoring is recommended in patients receiving treatment with mTOR inhibitors because mTOR inhibitors are accompanied by a high incidence of hyperglycemia and new-onset diabetes (13%–50%) when used as anticancer drugs [58]. The gene discussed is MTOR; the disease is Hyperglycemia.